Targeted Therapies for Solid Tumors: A Handbook for Moving Toward New Frontiers in Cancer Treatment (Current Clinical Pathology)

This volume provides readers a comprehensive and state-of-the-art overview about the range of applications of targeted therapies for solid tumors. The sections of the book have been structured to review the oncogene addicted tumors, the pharmacology and clinical development of new molecularly targeted agents, the use of biomarkers as prognostic, predictive and surrogate endpoints, and the evaluation of tumor response and specific malignancies treated with targeted agents. The book also covers some of the newest developments in cancer therapy that are not adequately covered by any current available literature. Written by recognized experts in the field, __Targeted Therapies for Solid Tumors: A Handbook for Moving Toward New Frontiers in Cancer Treatment__ provides a unique and valuable resource in the field of molecular oncology, both for those currently in training, and for those already in clinical or research practice. Front Matter....Pages i-x Introduction....Pages 1-1 Oncogene Addiction in Solid Tumors....Pages 3-7 Pharmacology and Clinical Development of New Molecularly Targeted Agents....Pages 9-29 Biomarkers as Prognostic, Predictive, and Surrogate Endpoints....Pages 31-41 Evaluation of Response in Malignant Tumors Treated with Targeted Agents....Pages 43-55 Targeted Therapies for HER2-positive Breast Cancer....Pages 57-72 Role of Poly ADP-Ribose Polymerase (PARP) Inhibitors in Triple-Negative Breast Cancer (TNBC)....Pages 73-80 Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck....Pages 81-87 Targeted Therapies for Non-Small Cell Lung Cancer....Pages 89-101 Targeted Therapies for Gastric Cancer....Pages 103-126 Targeted Therapies for Pancreatic Cancer....Pages 127-135 Targeted Therapies in Hepatocellular Carcinoma....Pages 137-145 Targeted Therapies for Colorectal Cancer....Pages 147-162 Targeted Therapy in Gastrointestinal Stromal Tumors....Pages 163-196 Targeted Therapies in Kidney Cancer....Pages 197-210 Targeted Therapies in Melanoma....Pages 211-227 Targeted Therapies for Prostate Cancer....Pages 229-248 Targeted Therapies for Bone Metastases....Pages 249-266 Back Matter....Pages 267-269 This volume provides readers a comprehensive and state-of-the-art overview about the range of applications of targeted therapies for solid tumors. The sections of the book have been structured to review the oncogene addicted tumors, the pharmacology and clinical development of new molecularly targeted agents, the use of biomarkers as prognostic, predictive and surrogate endpoints, and the evaluation of tumor response and specific malignancies treated with targeted agents. The book also covers some of the newest developments in cancer therapy that are not adequately covered by any current available literature. Written by recognized experts in the field, Targeted Therapies for Solid Tumors: A Handbook for Moving Toward New Frontiers in Cancer Treatment℗lprovides a unique and valuable resource in the field of molecular oncology, both for those currently in training, and for those already in clinical or research practice Evaluation of Response in Malignant Tumors Treated with Targeted AgentsRECIST 1.1; What to Measure?; Special Considerations Regarding Lesion Measurability:; How to Assess Disease Progression?; Response Criteria; When to Asses Disease?; Imaging Considerations; Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST); Limits of RECIST 1.1 in Target Therapies and Modern Criteria; Imaging Modalities; Tumor Response Criteria in Targeted Cancer Therapies; GIST; Hepatocellular Carcinoma; mRECIST and HCC; EASL Criteria and HCC; Malignant Melanoma; High-Grade Malignant Glioma; PERCIST Role of Poly ADP-Ribose Polymerase (PARP) Inhibitors in Triple-Negative Breast Cancer (TNBC)Poly ADP-ribose Polymerase Inhibitors, DNA Damage Repair Dysfunction, and the Synthetic Lethality; DDR Dysfunction and Clinically Relevant Biomarkers; DDR Dysfunction and Synthetic Lethality Through PARP Inhibition; Clinical Trials with PARP Inhibitors; Triple-Negative Breast Cancer (TNBC) and DDR Dysfunction; Clinical Trials with PARP Inhibitors in BC and TNBC; References; Chapter-8; Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck; EGFR-Directed Monoclonal Antibodies Agents Inhibiting AngiogenesisPharmacokinetics; Bioavailability; Metabolism and Clearance; Pharmacogenetics; Conclusions; References; Chapter-4; Biomarkers as Prognostic, Predictive, and Surrogate Endpoints; What Is a Biomarker?; Potential Clinical Applications of Cancer Biomarkers; Prognostic Biomarkers; Predictive Biomarkers; Surrogate Endpoints Biomarkers; Circulating Biomarkers: The Concept of "Liquid Biopsy"; Circulating Tumor Cells; Circulating Tumor DNA; New Perspectives and Future Applications; References; Chapter-5 Antonio Russo, Rafael Rosell, Christian Rolfo, Editors. Includes Bibliographical References And Index. Mode Of Access: World Wide Web.